2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0205A
    Saralasin acetate hydrate 39698-78-7
    Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension.
    Saralasin acetate hydrate
  • HY-P0295A
    Gly-Arg-Gly-Asp-Ser TFA 2828433-23-2
    Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ∼5 and ∼6.5 μM.
    Gly-Arg-Gly-Asp-Ser TFA
  • HY-P10021
    Tapderimotide 1221082-45-6
    Tapderimotide (hTERT (691–705)) is an immunological agent for active immunization.
    Tapderimotide
  • HY-P10048
    TAT-JIP 1623722-15-5
    TAT-JIP inhibits the phosphorylation of endogenous c-jun activated by PHA–PMA.
    TAT-JIP
  • HY-P10065
    RKLLW-NH2 289480-71-3
    RKLLW-NH2 is a Cathepsin L inhibitor.
    RKLLW-NH2
  • HY-P10074
    TAT-MEK1 566872-16-0
    TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. TAT-MEK1 IC50 in vitro for ERK2 is 29 μM.
    TAT-MEK1
  • HY-P10081
    CTP-NBD 1268513-27-4
    CTP-NBD is a cell permeable specific NFκB peptide inhibitor. CTP-NBD could be used in colitis study
    CTP-NBD
  • HY-P10085
    PKC-ε translocation inhibitor peptide
    PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking.
    PKC-ε translocation inhibitor peptide
  • HY-P10088
    Mouse TREM-1 SCHOOL peptide, control
    Mouse TREM-1 SCHOOL peptide, control is a negative control of Mouse TREM-1 SCHOOL peptide.
    Mouse TREM-1 SCHOOL peptide, control
  • HY-P10109
    G6PI 325-339 (human) 1174631-35-6
    G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms.
    G6PI 325-339 (human)
  • HY-P10111
    Histone H3K9me3 (1-15) 951011-30-6
    Histone H3K9me3 (1-15) (H3(1-15)K9me3) is a histone posttranslational modification (PTM) that has emerged as hallmark of pericentromeric heterochromatin. Trimethylation of histone H3 at lysine 9 is associated with gene repression, prevents transcription factor binding.
    Histone H3K9me3 (1-15)
  • HY-P10178
    Myristoylated ARF6 (2-13)
    Myristoylated ARF6 (2-13) blocks MyD88–ARNO–ARF6–signaling axis by deactivating ARF6.
    Myristoylated ARF6 (2-13)
  • HY-P10179
    ARF6 (2-13) 1026775-53-0
    ARF6 (2-13) is a peptide with a sequence of GKVLSKIFGNKE. ARF6 (2-13) is an inhibitor of ARF6. ARF6 (2-13) can be used in the research of endotoxemia.
    ARF6 (2-13)
  • HY-P10183
    CD36 Peptide P (139-155), Cys conjugated 143257-74-3
    CD36 Peptide P (139-155), Cys conjugated is a Cys labelled CD36 Peptide, and can inhibit the immunoadsorption of CD36 by OKM5.
    CD36 Peptide P (139-155), Cys conjugated
  • HY-P10184
    CD36 Peptide P (93-110), Cys conjugated 143257-75-4
    CD36 Peptide P (93-110), Cys conjugated is a Cys labelled CD36 Peptide, and can block binding of CD36 to immobilized thrombospondin and partially inhibited collagen-induced platelet aggregation.
    CD36 Peptide P (93-110), Cys conjugated
  • HY-P10185
    Antiflammin 3 118850-73-0
    Antiflammin 3 is an anti-inflammatory peptide 3 (MQMNKVLDS).
    Antiflammin 3
  • HY-P10203
    μ/κ/δ opioid receptor agonist 1
    μ/κ/δ opioid receptor agonist 1 is a μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor (DOR) agonist. μ/κ/δ opioid receptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test.
    μ/κ/δ opioid receptor agonist 1
  • HY-P10218
    MANS peptide 479482-23-0 99.85%
    MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis.
    MANS peptide
  • HY-P10219
    Brevicidine analog 22
    Brevicidine analog 22 (22) exerts broad spectrum antimicrobial activity and excellent stability (t1/2 = 40.98 h), with MICs of 2-16 μM for gram-negative and gram-positive bacteria.
    Brevicidine analog 22
  • HY-P10245
    Fusion glycoprotein (92-106) 406477-46-1
    Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratory syncytial virus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL).
    Fusion glycoprotein (92-106)
Cat. No. Product Name / Synonyms Application Reactivity